DewDiligence
2年前
MET reports 3Q22 results:
https://www.metlife.com/content/dam/metlifecom/us/homepage/about-us/newsroom/earnings-releases/Q3_2022_Earnings_News_Release.pdf
• Net income of $331 million, or $0.41 per share, compared to net income of $1.5 billion, or $1.77 per share, in the third quarter of 2021.
• Adjusted earnings of $966 million, or $1.21 per share, compared to adjusted earnings of $2.1 billion, or $2.39 per share, in the third quarter of 2021.
• Book value of $27.00 per share, down 65 percent from $77.24 per share at September 30, 2021.
• Book value, excluding accumulated other comprehensive income (AOCI) other than foreign currency translation adjustments (FCTA), of $54.37 per share, down 5 percent from $57.29 per share at September 30, 2021.
• Return on equity (ROE) of 4.9 percent.
• Adjusted ROE, excluding AOCI other than FCTA, of 8.9 percent.
• Holding company cash and liquid assets of $5.2 billion at September 30, 2022, which is above the target cash buffer of $3.0 - $4.0 billion.
DewDiligence
3年前
MET analysis—1Q22 non-GAAP EPS was -15% YoY due to weaker (but still objectively strong) results in private-equity investments. In #msg-167739042, I asked rhetorically how long MET could continue to post superlative results from private equity. Now, we’re seeing a regression to the mean (or perhaps worse).
MET’s insurance business benefits from higher interest rates insofar as MET is effectively short fixed income (i.e. it has net liabilities for eventual insurance claims). However, in recent quarters, the gains on MET’s private-equity investments have outweighed the interest-rate effect mentioned above.
All told, I’m not especially bullish on MET; however, I manage a portfolio that has a MET position with a cost basis of zero, stemming from MET’s de-mutualization in 2001.
DewDiligence
4年前
MET—(-6%/AH)—reports 2Q20 results—the main negative in the quarter was not COVID-19 claims, but rather losses on private equity and derivative securities:
https://finance.yahoo.com/news/metlife-announces-second-quarter-2020-201500963.html
https://s23.q4cdn.com/579645270/files/doc_financials/2020/q2/MET_2Q20_Supplemental_Slides-FINAL.pdf
https://finance.yahoo.com/news/metlife-quarterly-profit-nosedives-lower-201514460.html MetLife said it had higher COVID-related claims during the quarter, but did not provide specifics. The disease's effects in the third quarter would be largely offset by underwriting margins, the company said.
MetLife reported $710 million in net derivative losses, compared with $724 million in derivative gains a year ago. That’s a $1.43B negative swing, YoY, but I can’t really complain insofar as MET gained $4.2B on derivatives during 1Q20 (#msg-155475813).
DewDiligence
5年前
MET boosts dividend—forward yield=5.2%:
https://finance.yahoo.com/news/metlife-increases-common-stock-dividend-201500280.html MetLife, Inc…today announced that its Board of Directors has declared a second quarter 2020 common stock dividend of $0.46 per share, an increase of 4.5 percent from the first quarter common stock dividend of $0.44 per share. The dividend will be payable on June 12, 2020, to shareholders of record as of May 8, 2020. The new annualized payout is $1.84, which is 5.2% of the current share price ($35.18).